Outcomes | Timea | Groupa | Interaction | ||||||
---|---|---|---|---|---|---|---|---|---|
f | p-value | ηp2 | f | p-value | ηp2 | f | p-value | ηp2 | |
(1–27) | (1–27) | (1–27) | |||||||
Clinical measures | |||||||||
 FDS | 103.15 |  < 0.001 | 0.79 | 5.17 | 0.031 | 0.16 | 26.95 |  < 0.001 | 0.5 |
 SCWT | 58.05 |  < 0.001 | 0.68 | 3.35 | 0.078 | 0.11 | 4.58 | 0.041 | 0.15 |
 WR | 47.89 |  < 0.001 | 0.64 | 5.47 | 0.027 | 0.17 | 20.4 |  < 0.001 | 0.43 |
 NWR | 33.94 |  < 0.001 | 0.56 | 3.66 | 0.067 | 0.12 | 14.45 | 0.001 | 0.35 |
 PD | 69.08 |  < 0.001 | 0.72 | 2.61 | 0.118 | 0.09 | 13.37 | 0.001 | 0.33 |
 TC | 154.79 |  < 0.001 | 0.85 | 4.94 | 0.035 | 0.16 | 15.48 | 0.001 | 0.36 |
 CW | 103.15 |  < 0.001 | 0.6 | 2.15 | 0.154 | 0.07 | 14.47 | 0.001 | 0.35 |
CoP measures | |||||||||
 QO-L (cm) | 0 | 0.972 | 0 | 2.45 | 0.13 | 0.08 | 4.48 | 0.044 | 0.14 |
 QO-A (cm2) | 1.37 | 0.252 | 0.05 | 0.73 | 0.401 | 0.03 | 19.11 |  < 0.001 | 0.41 |
 QO-MV (cm/s) | 0 | 0.993 | 0 | 2.41 | 0.132 | 0.08 | 4.39 | 0.046 | 0.14 |
 QO-AP (SD) | 0.07 | 0.79 | 0 | 1.1 | 0.305 | 0.04 | 10.05 | 0.004 | 0.27 |
 QO-ML (SD) | 3.97 | 0.056 | 0.13 | 0.11 | 0.747 | 0 | 9.25 | 0.005 | 0.26 |
 QC-L (cm) | 4.07 | 0.054 | 0.13 | 0.23 | 0.635 | 0.01 | 0.1 | 0.752 | 0 |
 QC-A (cm2) | 0.31 | 0.584 | 0.01 | 0.15 | 0.704 | 0.01 | 4.52 | 0.043 | 0.14 |
 QC-MV (cm/s) | 4.51 | 0.043 | 0.14 | 0.27 | 0.608 | 0.01 | 0.18 | 0.674 | 0.01 |
 QC-AP (SD) | 0.04 | 0.842 | 0 | 0.14 | 0.711 | 0.01 | 8.34 | 0.008 | 0.24 |
 QC-ML (SD) | 3.41 | 0.076 | 0.11 | 0.05 | 0.83 | 0 | 0.45 | 0.511 | 0.02 |